In Silico临床试验市场 - 全球产业规模、份额、趋势、竞争格局、机会及预测（按产业、治疗领域、地区和竞争格局划分，2021-2031年）

全球In Silico临床试验市场预计将从 2025 年的 45.8 亿美元成长到 2031 年的 72.2 亿美元，复合年增长率为 7.88%。

此领域利用电脑建模和模拟技术，在虚拟病患群中评估药物和医疗设备的疗效和安全性，评估过程可与人体试验同步进行，也可先于人体试验。推动该市场发展的关键因素包括传统研发成本的不断攀升、减少动物试验的伦理要求，以及缩短新治疗方法上市时间的需求。根据药物资讯协会 (DIA) 2024 年引用的一项专家分析显示，在某些研发阶段，采用此类计算模拟技术可将效率提高高达 90%。

然而，阻碍市场成长的一大障碍是这些计算模型监管检验的复杂性。证明虚拟模拟模型的可靠性符合严格的监管要求仍然是一项复杂的挑战，这主要是因为目前用于验证这些模型预测准确性（以实际人类生物数据为依据）的行业框架仍处于起步阶段。缺乏成熟的检验标准对商业性应用构成了重大障碍。

市场驱动因素

传统临床试验成本和复杂性的不断增加是推动製药业转向In Silico方法的主要驱动因素。随着生物标的日益复杂，进行大规模的实体试验的经济负担变得难以承受，因此需要建立虚拟队列，以便在人体试验前评估疗效。生成式工作流程的最新趋势凸显了缩短研发週期的必要性，这些工作流程使企业能够绕过冗长的传统步骤。例如，在2024年3月的新闻稿中， In Silico Medicine公司报告称，发表在《自然·生物技术》杂誌上的一项研究表明，其人工智慧平台在大约18个月内识别出了候选治疗药物。这显着缩短了通常长达数年的临床前研究週期，表明计算模型可以降低后期研发失败的风险并改善资源管理。

此外，人工智慧和高效能运算的快速发展透过提高虚拟模拟的预测精度，推动了市场成长。从静态模型到动态生成演算法的转变，使得创建能够模拟人体生理反应的高精度数位双胞胎模型成为可能。 2024年5月，GoogleDeepMind发布了升级版的「AlphaFold 3」模型，该模型将蛋白质-分子相互作用预测的准确率提高了50%，提供了可靠虚拟测试所需的详细数据。基于这项技术进步，Xaira Therapeutics于2024年4月成立，投资超过10亿美元，并大力投资以扩展这些能力，并将这些先进的计算技术融入药物研发的整个生命週期。

市场挑战

计算模型获得监管部门核准的复杂流程是全球In Silico临床试验市场成长的一大障碍。儘管模拟技术在理论上具有很高的效率，但要证明这些虚拟方法能够满足严格的安全标准仍然极具挑战性。监管机构要求提供强有力的证据，证明电脑模型可以准确预测人体生物反应，但目前业界缺乏一套完善的标准化框架来持续证明这种可靠性。因此，药物研发者在核准过程中面临巨大的不确定性和被拒风险，这阻碍了他们投入必要的资金从传统方法过渡到虚拟患者群。

由于缺乏用于模型检验的高品质真实世界数据，这项挑战更加严峻。与精确的人类生物数据集进行广泛的基准测试对于确认预测准确性至关重要，但此类数据通常分散或难以获得。根据皮斯托亚联盟2024年的调查，52%的生命科学专业人士认为低品质且控制不佳的资料集是采用这些先进计算技术的主要障碍。缺乏可靠的检验数据直接加剧了监管方面的挑战，阻碍了企业累积市场核准所需的有力证据，并延缓了In Silico测试的商业性化应用。

市场趋势

为虚拟患者群体创建高精度数位双胞胎，从根本上改变了监管申报流程，使开发人员无需招募患者即可模拟药物在不同生理人群中的表现。这种转变在广泛应用基于生理的药物动力学模型生成虚拟队列方面尤其明显，这些模型能够预测特定族群（例如儿童患者或器官功能受损患者）的药物交互作用。因此，製药公司越来越多地直接使用这些模拟来获得适应症核准，实际上取代了某些体内研究。正如 Certara 在 2024 年 9 月发布的「Simcyp 联盟成立 25 週年」公告中所指出的，其平台生成的模拟已成功指导了 115 种药物的 375 多项适应症决策，取代了实际的临床试验。

同时，虚拟对照组的使用正在重新定义试验设计，使申办者能够以基于历史临床记录产生的合成数据取代传统的安慰剂组。这种方法在肿瘤学和罕见疾病研究领域已被广泛应用，因为在这些领域，招募足够数量的受试者来建立标准对照组往往在伦理上具有挑战性，或在实践中难以实现。透过利用庞大的历史资料集，研究人员可以建立统计上有效的外部对照组，从而在保持科学严谨性的同时，显着减少患者招募的需求。根据Medidata公司2024年8月发布的报告《符合监管要求的外部对照组》，该公司用于创建这些合成对照组的专有资料库目前包含来自超过33,000项临床试验和1000多万名患者的历史临床试验数据，为这些混合试验模型提供了必要的详细证据。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球In Silico临床试验市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按行业划分（医疗设备与药品）
  • 依治疗领域（肿瘤科、神经科、心臟科、感染疾病、整形外科、皮肤科、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美In Silico临床试验市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲In Silico临床试验市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区In Silico临床试验市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲In Silico临床试验市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲In Silico临床试验市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球In Silico临床试验市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Dassault Systemes
• Certara
• Insilico Medicine
• GNS Healthcare
• Siemens Healthineers
• Evidera
• Novadiscovery
• Simulations Plus
• Genentech
• Physiomics

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global In Silico Clinical Trials Market is projected to expand from USD 4.58 Billion in 2025 to USD 7.22 Billion by 2031, reflecting a compound annual growth rate of 7.88%. This sector employs computer modeling and simulation to assess the efficacy and safety of pharmaceuticals and medical devices within virtual patient groups, occurring either alongside or prior to human testing. Key factors propelling this market include the escalating expenses associated with traditional research and development, the ethical imperative to minimize animal testing, and the necessity to expedite new therapies' time to market. Expert analysis cited by the Drug Information Association in 2024 suggests that incorporating these computational simulations could boost efficiency by up to 90% during certain developmental phases.

However, a major obstacle hindering market growth is the intricate nature of regulatory validation for these computational models. Demonstrating the reliability of virtual simulations to meet strict regulatory requirements remains a complex task, primarily because industry frameworks for confirming the predictive accuracy of these models against actual human biological data are still evolving. This lack of mature verification standards creates a significant barrier to widespread commercial adoption.

Market Driver

The rising expense and intricacy of conventional clinical trials are the main factors driving the pharmaceutical sector toward in silico methods. As biological targets grow more complex, the financial strain of running extensive physical trials has become unmanageable, necessitating virtual cohorts that can evaluate efficacy prior to human involvement. This need to shorten development cycles is highlighted by recent advancements in generative workflows that enable companies to skip prolonged traditional steps. For instance, Insilico Medicine reported in a March 2024 press release regarding a study in 'Nature Biotechnology' that their AI-powered platform identified a therapeutic candidate in roughly 18 months, a timeframe notably shorter than the standard multi-year preclinical period, demonstrating how computational models can lower the risk of late-stage failures and improve resource management.

Furthermore, rapid developments in artificial intelligence and high-performance computing are fueling market growth by improving the predictive accuracy of virtual simulations. Moving from static models to dynamic, generative algorithms enables the creation of highly precise digital twins that mimic human physiological reactions. In May 2024, Google DeepMind announced that their upgraded 'AlphaFold 3' model secured a 50% increase in prediction accuracy for protein-molecule interactions, offering the detailed data needed for dependable virtual testing. This technological progress has prompted significant investment to scale these capabilities, as seen in April 2024 when Xaira Therapeutics launched with over USD 1 billion in committed capital to embed these advanced computational techniques into the entire drug development lifecycle.

Market Challenge

The intricate process of obtaining regulatory validation for computational models poses a significant barrier to the growth of the Global In Silico Clinical Trials Market. Although simulation technologies promise theoretical efficiency, proving the credibility of these virtual approaches to meet rigorous safety standards remains challenging. Regulatory authorities demand solid proof that computer models can precisely forecast human biological responses, yet the sector currently lacks fully developed, standardized frameworks to consistently prove this reliability. As a result, pharmaceutical developers encounter considerable uncertainty and the threat of rejection during approval procedures, which deters the financial commitment needed to shift from conventional techniques to virtual patient cohorts.

This challenge is further compounded by the struggle to access high-quality real-world data required to verify these models. Confirming predictive accuracy necessitates extensive benchmarking against exact human biological datasets, which are frequently fragmented or inaccessible. According to the Pistoia Alliance in 2024, 52% of life science professionals identified low-quality and poorly curated datasets as the primary obstacle to implementing these sophisticated computational technologies. This lack of reliable validation data directly worsens regulatory difficulties, hindering companies from compiling the strong evidence dossiers required for market approval and delaying the commercial uptake of in silico trials.

Market Trends

The creation of high-fidelity digital twins for virtual patient cohorts is fundamentally transforming regulatory submissions by enabling developers to model drug performance across varied physiological populations without the need for human recruitment. This shift is especially apparent in the broad use of physiologically based pharmacokinetic modeling, which creates virtual cohorts to forecast drug interactions in specific demographics, such as pediatric patients or individuals with organ impairment. Consequently, pharmaceutical firms are increasingly utilizing these simulations to obtain label approvals directly, effectively substituting for certain in vivo studies. As noted by Certara in their September 2024 'Simcyp Consortium Celebrates 25th Anniversary' announcement, their platform's simulations have successfully guided dosing decisions for over 375 label claims covering 115 different drugs, replacing physical clinical trials.

Concurrently, the use of virtual control arms is redefining trial design by allowing sponsors to replace conventional placebo groups with synthetic data generated from historical clinical records. This method is gaining considerable momentum in oncology and rare disease research, where enrolling enough participants for standard control arms is often ethically difficult or logistically impractical. By leveraging extensive historical datasets, researchers can build statistically sound external comparators that uphold scientific rigor while significantly lowering patient enrollment needs. According to Medidata's August 2024 report on 'The Regulatory Grade External Control Arm', their proprietary database for creating these synthetic arms now includes historical clinical trial data from more than 33,000 trials and 10 million patients, offering the detailed evidence needed to sustain these hybrid trial models.

Key Market Players

• Dassault Systemes
• Certara
• Insilico Medicine
• GNS Healthcare
• Siemens Healthineers
• Evidera
• Novadiscovery
• Simulations Plus
• Genentech
• Physiomics

Report Scope

In this report, the Global In Silico Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

In Silico Clinical Trials Market, By Industry

• Medical Devices v/s Pharmaceuticals

In Silico Clinical Trials Market, By Therapeutic Area

• Oncology
• Neurology
• Cardiology
• Infectious Diseases
• Orthopedic
• Dermatology
• Others

In Silico Clinical Trials Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global In Silico Clinical Trials Market.

Available Customizations:

Global In Silico Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global In Silico Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Industry (Medical Devices v/s Pharmaceuticals)
  • 5.2.2. By Therapeutic Area (Oncology, Neurology, Cardiology, Infectious Diseases, Orthopedic, Dermatology, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America In Silico Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Industry
  • 6.2.2. By Therapeutic Area
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States In Silico Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Industry
      • 6.3.1.2.2. By Therapeutic Area
  • 6.3.2. Canada In Silico Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Industry
      • 6.3.2.2.2. By Therapeutic Area
  • 6.3.3. Mexico In Silico Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Industry
      • 6.3.3.2.2. By Therapeutic Area

7. Europe In Silico Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Industry
  • 7.2.2. By Therapeutic Area
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany In Silico Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Industry
      • 7.3.1.2.2. By Therapeutic Area
  • 7.3.2. France In Silico Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Industry
      • 7.3.2.2.2. By Therapeutic Area
  • 7.3.3. United Kingdom In Silico Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Industry
      • 7.3.3.2.2. By Therapeutic Area
  • 7.3.4. Italy In Silico Clinical Trials Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Industry
      • 7.3.4.2.2. By Therapeutic Area
  • 7.3.5. Spain In Silico Clinical Trials Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Industry
      • 7.3.5.2.2. By Therapeutic Area

8. Asia Pacific In Silico Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Industry
  • 8.2.2. By Therapeutic Area
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China In Silico Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Industry
      • 8.3.1.2.2. By Therapeutic Area
  • 8.3.2. India In Silico Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Industry
      • 8.3.2.2.2. By Therapeutic Area
  • 8.3.3. Japan In Silico Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Industry
      • 8.3.3.2.2. By Therapeutic Area
  • 8.3.4. South Korea In Silico Clinical Trials Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Industry
      • 8.3.4.2.2. By Therapeutic Area
  • 8.3.5. Australia In Silico Clinical Trials Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Industry
      • 8.3.5.2.2. By Therapeutic Area

9. Middle East & Africa In Silico Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Industry
  • 9.2.2. By Therapeutic Area
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia In Silico Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Industry
      • 9.3.1.2.2. By Therapeutic Area
  • 9.3.2. UAE In Silico Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Industry
      • 9.3.2.2.2. By Therapeutic Area
  • 9.3.3. South Africa In Silico Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Industry
      • 9.3.3.2.2. By Therapeutic Area

10. South America In Silico Clinical Trials Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Industry
  • 10.2.2. By Therapeutic Area
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil In Silico Clinical Trials Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Industry
      • 10.3.1.2.2. By Therapeutic Area
  • 10.3.2. Colombia In Silico Clinical Trials Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Industry
      • 10.3.2.2.2. By Therapeutic Area
  • 10.3.3. Argentina In Silico Clinical Trials Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Industry
      • 10.3.3.2.2. By Therapeutic Area

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global In Silico Clinical Trials Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Dassault Systemes
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Certara
• 15.3. Insilico Medicine
• 15.4. GNS Healthcare
• 15.5. Siemens Healthineers
• 15.6. Evidera
• 15.7. Novadiscovery
• 15.8. Simulations Plus
• 15.9. Genentech
• 15.10. Physiomics

16. Strategic Recommendations

17. About Us & Disclaimer